Enovis Details Robotics Strategy and Amplitude Surgical Acquisition at Wells Fargo Conference

U.S. Market Normalization and European Growth

Market conditions in the United States have returned to pre-pandemic seasonality, featuring traditional summer slowdowns, according to management statements at the conference. Enovis reported a strong reconstruction segment in the first half of 2026 with an organic growth rate, while projecting growth for the segment in the second half of the year. Chief Executive Officer Damien McDonald noted that the company’s customer mix insulates it from disruptions tied to the Affordable Care Act that have impacted competitors. In Europe, despite slower macroeconomic indicators and regional headwinds like defense budget shifts, Enovis stated it continues to outpace the broader market, particularly in shoulder procedures.

Amplitude Surgical Acquisition and Robotics Roadmap

To scale its surgical capabilities, Enovis plans to close its acquisition of France-based Amplitude Surgical in the fourth quarter of 2026. Management cited a mismatch between existing shoulder robotics form factors and the practical demands of surgeons and patients as the primary driver for a new approach. The transaction integrates Amplitude’s Grenoble-based engineering team and technology with Enovis’s existing ARVIS planning and navigation platform. According to company disclosures, the combined technology will support both hospital and ambulatory surgery center environments, with a U.S. market launch for the knee robot planned for 2028.

Financial Outlook, Margins, and Debt Ratios

Chief Financial Officer Ben Berry reported that the company’s debt-to-EBITDA ratio improved from 3.8x to 3.1x ahead of the transaction. The upcoming acquisition of Amplitude Surgical will temporarily push leverage to approximately 3.5x before returning downward toward 3.1x. Enovis maintains a revolving credit facility of a substantial amount to fund the purchase through cash and debt. For the upcoming fiscal year, management forecasts a 100-basis-point contraction in EBITDA margin—partially offset by 50 basis points of underlying operational improvements—alongside a jump in free cash flow conversion, representing roughly $100 million in absolute cash flow.

Frequently Asked Questions

• When is the Amplitude Surgical acquisition expected to close? According to Enovis management, the transaction is scheduled to close in the fourth quarter of 2026.
• What is the projected free cash flow conversion rate for Enovis? The company guides to a free cash flow conversion rate for next year, scaling to a higher percentage by 2029.
• How does Enovis plan to finance the transaction? Enovis will utilize a mix of cash generated from operations and debt drawn from its revolving credit facility.